Flow Cytometry Assay Service for Monitoring Cytokine Release in In Vivo CAR-T Therapy

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Our laboratory specializes in flow cytometry work, with a core focus on tracking cytokine dynamics throughout CAR-T cell research. When working with complex animal models, our team can capture abrupt shifts in cytokine levels. Beyond that, we are able to distinguish distinct cell populations that trigger unwanted toxic immune responses within test subjects. We combine multi-parameter intracellular staining with well-tested gating methods to map the varied functional traits of CAR-T cells. With these analytical approaches in place, research teams can spot early warning signs of Cytokine Release Syndrome, a common risk in related studies. Data collected from our lab work delivers tangible references for ongoing research, and it also pushes the real-world application of modern immunotherapy forward step by step.

Introduction

CAR-T therapy targeting CD19 has shown promise for patients with refractory hematological malignancies, but managing adverse reactions like CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant challenge. To mitigate human errors in multi-center research, pre-formulated dry antibody kits are commonly used for high-parameter flow tests. However, rapid immune cell expansion can lead to severe toxic effects, making comprehensive preclinical animal testing essential. Researchers typically use high-dimensional flow cytometry for long-term dynamic tracking to establish safety boundaries for CAR-T treatments.

Fig.1 How CAR-T Cells Trigger Cytokine Release Syndrome: Mechanisms and Pathways. (OA Literature) Fig.1 Mechanism of CAR-T cell-induced CRS.¹

Our Service

Rigorous analytical testing is essential to evaluate the efficacy and toxicity of CAR-T products. Creative Biolabs offers a comprehensive suite of multi-parameter flow cytometry solutions using preclinical models and clinical samples. This allows researchers to continuously monitor CAR-T cell proliferation, phenotypes, and functional dynamics within the biological microenvironment.

To address the common challenge of incomplete data during R&D, our standardized workflows fill critical data gaps. By measuring target cell clearance and cytokine production in peripheral blood and local tissues, we ensure that localized excessive immune activation is never overlooked.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Whether your CAR-T project is in the translational phase or clinical trials, our team provides fully customized, one-stop flow cytometry services for in vivo cytokine release monitoring. We flexibly adjust antibody panels, assay frameworks, and gating strategies to precisely match your unique CAR structure and phase-specific regulatory requirements.

Analysis of Flow Cytometry Assays for Monitoring Cytokine Release in In Vivo CAR-T Therapy. (Creative Biolabs Original)

Our Workflow

All testing procedures follow unified operational specifications. Even when projects face tight delivery schedules, our team can generate stable and reproducible cellular analysis data consistently. The complete workflow acts as a reliable bridge, connecting raw biological specimens to quantitative analysis results that meet clinical industry standards.

Required Starting Materials: If you plan to launch our testing services, you may provide cryopreserved or fresh whole blood samples. Tissue suspensions isolated from humanized mouse models, such as spleen and bone marrow specimens, are also acceptable. Clients can also submit pre-infusion profile files of CAR-T batches and relevant transgene sequence data.

Workflow of Flow Cytometry Assays for Monitoring Cytokine Release in In Vivo CAR-T Therapy. (Creative Biolabs Original)

Final Deliverables: Once all testing tasks are completed, clients will receive a full package of analysis documents. This package includes fully annotated digital gating files, standard statistical reports that correlate cell expansion trends with myeloid cell cytokine responses, and a concise biostatistical summary that defines clear safety thresholds.

Benefits

Customized High-Parameter Panel Design: We design and validate bespoke 15-28+ color panels tailored to your specific CAR construct, target antigens, and tissue types.
Species-Specific Cytokine Discrimination: Proprietary staining protocols and antibody selections to distinguish between human CAR-T-derived cytokines and murine host-derived inflammatory responses in xenograft models.
Comprehensive Intracellular Cytokine Staining (ICS): Optimized re-stimulation and protein transport inhibition protocols to maximize the detection of transient cytokine signals in vivo.
Polyfunctional Profiling: Detailed analysis of multi-cytokine production at the unicellular level, providing a " functional fingerprint" of your therapy's potency.
Longitudinal In Vivo Monitoring: Standardized procedures for serial blood draws and tissue harvesting (spleen, bone marrow, TILs) to track cytokine release kinetics over time.

FAQs

Q1: How do dry-format antibody panels improve data quality over liquid cocktails?

A: They use stabilized, pre-fixed antibody layers that eliminate pipetting errors, reagent degradation, and batch variations, ensuring highly stable baselines across multi-site projects.

Q2: Can this assay differentiate CAR-T-driven cytokines from host immune responses?

A: Yes. By utilizing 13-color panels in humanized models, the assay simultaneously tracks human intracellular markers and host myeloid markers to map cellular cross-talk.

Q3: What parameters assess the long-term exhaustion profile of persisting cells?

A: The panels combine co-stimulatory tracking with specific exhaustion networks, monitoring surface marker co-expression across naive, memory, and effector T-cell populations.

Q4: Are automated gating templates compatible with custom exploratory endpoints?

A: Yes. The open-architecture design allows for seamless "drop-in" custom targets without disrupting the validated, standardized baseline parameters.

Q5: How does flow cytometry compare to qPCR/dPCR for tracking persistent cells?

A: PCR only quantifies transgene copy numbers. Flow cytometry simultaneously delivers protein expression, viable phenotypic subsets, and functional activation statuses.

Partner with Us

We have developed advanced flow cytometry testing solutions, which focus on monitoring cytokine release during in vivo CAR-T research. These professional tools can fully meet researchers' demands for real-time tracking of cytokine surges and cell-related toxic events. We apply high-dimensional intracellular staining and refined gating rules to help research teams analyze dynamic changes in CAR-T cells and assess potential CRS risks in advance. In the long run, our professional support can effectively enhance both the safety and overall clinical value of your therapeutic products.

Contact our team for more information and to discuss your project needs, assay customization, data analysis strategies, and comprehensive solutions for your CAR-T therapy development programs.

Reference

Giavridis, Theodoros et al. "CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade."Nature Medicine vol. 24,6 (2018): 731-738. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1038/s41591-018-0041-7

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.